TrialEuropean journal of cancer (Oxford, England : 1990)2021

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.

Mark Clemons et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.